Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.

ABSTRACT:

Unlabelled

Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly delayed-release formulation of risedronate given before or following breakfast was non-inferior to traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient regimen for oral bisphosphonate therapy.

Introduction

We report the results of a randomized, controlled, clinical study assessing the efficacy and safety of a delayed-release (DR) 35 mg weekly oral formulation of risedronate that allows patients to take their weekly risedronate dose before or immediately after breakfast.

Methods

Women with postmenopausal osteoporosis were randomly assigned to receive rised

SUBMITTER: McClung MR 

PROVIDER: S-EPMC3249191 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature